Drugs and patents in ATC class H01BA - Vasopressin and analogues

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
DDAVP	desmopressin acetate
DESMOPRESSIN ACETATE	desmopressin acetate
DESMOPRESSIN ACETATE PRESERVATIVE FREE	desmopressin acetate
CONCENTRAID	desmopressin acetate
DESMODA	desmopressin acetate
DDAVP (NEEDS NO REFRIGERATION)	desmopressin acetate
>Tradename	>Generic Name

Last updated: June 14, 2026

Vasopressin and analogues remain a small, price-sensitive segment with limited blockbuster exposure. Patent coverage is largely driven by (1) individual branded products and their specific formulations/devices, (2) method-of-use (notably for diabetes insipidus dosing paradigms and perioperative indications), and (3) manufacturing-related claims that can constrain generic “workalikes.” Generic entry risk is product-specific and depends on Orange Book listings and the presence of enforceable unexpired patents at the filing time of any ANDA.

What products define ATC H01BA (vasopressin and analogues) commercialization risk?

Featured snippet: The H01BA class is led commercially by vasopressin and selective analogs (commonly used for diabetes insipidus and perioperative indications such as variceal bleeding protocols and shock/cardiac contexts, depending on jurisdiction and local guidance). The patent estate and generic risk are evaluated per product, not per ATC class.

Which actives typically sit inside H01BA

H01BA is consistently associated with vasopressin and its clinically used analogues (examples seen across formularies include desmopressin and terlipressin in many classification mappings; exact inclusion in H01BA versus other ATC subgroups depends on national ATC maintenance). Commercial and patent enforcement, however, remains product- and label-specific in practice.

Where market dynamics usually concentrate

Low to mid single-digit SKU counts per country driven by narrow indications and entrenched hospital formularies.
Wholesale price pressure in countries with procurement tenders and active generic substitution.
Device and route constraints (injectable vials vs nasal formulations), where “same active, different delivery” can still face formulation and device-lock claims.

How do vasopressin and analogues patents typically structure across the lifecycle?

Featured snippet: Patent estates for vasopressin and analogues tend to be segmented into composition/formulation, device/delivery, and method-of-use. Late-cycle continuation patents and manufacturing claims often extend enforceability even after initial active-ingredient patents expire.

Core patent buckets for this class

1) Composition and analog identity

Early patents typically protect the analog itself, the chemical structure, and its pharmaceutical acceptability.
For generics, the practical effect is that “active ingredient” patents often clear earlier than formulation-specific barriers.

2) Formulation and concentration

Injectable concentration ranges, pH control, stabilizers, and osmolarity specifications can support enforceable formulation claims.
For vasopressin-like peptides, excipient selection and water activity targets are frequently the claim focus.

3) Method-of-use and dosing regimens

Claims can cover dose titration schedules for diabetes insipidus or perioperative workflows.
Generic risk is lower for label-carved products but increases when ANDAs rely on the same therapeutic indication.

4) Manufacturing and purification

Process claims can include peptide synthesis steps, purification profiles, and sterility assurance steps.
Even when the drug product appears “simple,” process claims can constrain “non-infringing” routes.

What this means for generic entry

For a generic to avoid infringement, it must clear not only active-ingredient patents but also any remaining formulation/process claims tied to the specific product presentation.
“Label carve-outs” (procedural noninfringement by excluding certain indications) can reduce exposure, but they do not eliminate formulation/process infringement.

When does vasopressin and analogue exclusivity end (US patent term and regulatory exclusivity)?

Featured snippet: Exclusivity timing is best modeled per product using two clocks: (1) patent expiration for Orange Book-listed patents and (2) regulatory exclusivity (Hatch-Waxman exclusivities) tied to the specific NDA. The ATC class itself does not determine a single exclusivity timeline.

US exclusivity mechanics that matter

Hatch-Waxman Orange Book drives generic triggers because ANDA filers certify to unexpired patents via Paragraph IV, Paragraph III, or carve-outs.
OTC/compounded and hospital-use procurement can continue during patent life, but statutory generic competition accelerates after carve-outs expire and enforceable patents lapse.

Practical commercialization sequencing

At least 18 months of generic marketing exclusivity can be obtained after a successful Paragraph IV for certain products (subject to forfeiture rules).
First generic’s launch usually pressures branded pricing quickly in tendered markets.
Second and subsequent ANDAs typically follow within 1–3 years depending on litigation outcomes and the breadth of remaining formulation patents.

What Orange Book status applies to vasopressin products and analogues in the US?

Featured snippet: Orange Book listings are product-specific; evaluation requires mapping each branded NDA to its unexpired Orange Book patents and their listed dosage forms.

How to read the Orange Book for this class

For vasopressin and analogues, focus on:

Drug substance vs drug product patents (delivery and formulation often extend longer than the analog identity).
Method-of-use patents (common in dosing regimens).
Expiration dates and patent numbers listed for each dosage form (injectable vials, nasal solutions, etc.).

Why H01BA patents behave like “dose-form lock”

Even where two products use the same active ingredient, the Orange Book can list patents per presentation. A generic matching one presentation may still require litigation clearance for another (for example, nasal versus injectable).

Which patents protect formulations and devices for vasopressin and analogues?

Featured snippet: The enforceability hotspot is usually drug product formulation and administration device interfaces (device, extractables/leachables controls, container closures, and stability specifications).

Typical formulation claim themes

Buffer system and pH targets that maintain peptide stability.
Antioxidants or chelating agents that prevent degradation.
Sterility assurance and antimicrobial strategy, especially for multi-dose systems.
Stabilization through lyophilization matrix choices (where applicable).

Container closure and stability claims

Container composition, seal integrity, and storage stability profiles can be tied to patents.
For injectable peptides, claims can cover stability at defined temperature excursions and post-reconstitution timelines.

Which method-of-use patents drive infringement risk for diabetes insipidus and perioperative use?

Featured snippet: Method-of-use patents can materially affect ANDA litigation because they target the therapeutic indication and dose schedule rather than just chemical identity.

High-risk indication patterns

Diabetes insipidus: claims around dose titration algorithms, monitoring frequency, or specific patient subgroups.
Perioperative hemostasis/vascular indications (label dependent): claims aligned with dosing thresholds and administration timing.
Hospital administration protocols: patents can target specific administration sequences.

Design-around vs label carve-outs

If a generic can legitimately omit a claimed indication, it may reduce method-of-use risk while still facing formulation/process claims.
If the method-of-use patent is broad and tied to administration route, generic substitutions can still trigger disputes.

How strong is the patent estate for vasopressin analogues versus generics?

Featured snippet: Patent strength is usually uneven. The analog-identity layer may be weaker or expired; enforceability commonly shifts to formulation and process claims with remaining term and broader claim scope.

Strength indicators used in licensing and litigation

Number of unexpired Orange Book patents per product presentation.
Claim type distribution: drug product and process claims often raise the infringement bar.
Claim breadth: concentration ranges and pH/excipient definitions can be narrow enough to design around or broad enough to block meaningful substitution.
Litigation history: settlement patterns reveal whether courts and the patent holder view claims as readily enforceable.

What tends to happen commercially

When multiple patents remain, generics typically bid on later entries or seek licensing.
Where only a few patents remain and they are clearly design-aroundable, Paragraph IV challenges become more common.

What generic entry risks exist for vasopressin and analogues if patents remain unexpired?

Featured snippet: Generic risk is dominated by the remaining unexpired patents on the exact dosage form and the claim category used against the ANDA (product formulation vs method-of-use vs process).

Risk matrix (product-agnostic template)

Risk driver	If strong, likely outcome	What to look for
Drug product formulation patents remain	Delayed launch or licensed entry	Orange Book drug product patents with long remaining term
Method-of-use patents remain and align to label	Higher litigation probability	ANDA indications matching patented claim language
Manufacturing/process patents remain	Settlement or non-infringing process redesign	Surviving process claims and evidence of equivalence
Narrow concentration/pH claim scopes	Potential design-around	Patents limited to specific ranges
Prior Paragraph IV history	Faster assessment of likely settlement	Litigation outcomes by product

What Paragraph IV challenges and patent litigations typically affect this class?

Featured snippet: Litigation is usually concentrated at the product level after patent expiration approaches, with disputes tied to formulation and method-of-use rather than chemical identity.

Common litigation themes

Claim construction around excipients, pH, and stability requirements.
“Infringing equivalent” arguments for generic manufacturing processes.
Indication alignment for method-of-use patents.

Settlement economics pattern

Settlements often trade early launch against ongoing royalty or market entry scheduling.
The presence of multiple patents tends to push settlements toward either broad licensing or delayed launch with carve-outs.

How do biosimilars apply to ATC H01BA vasopressin analogues?

Featured snippet: Biosimilar frameworks generally do not apply to small-molecule or non-biologic peptide drugs unless the active is approved as a biologic under the Biologics Price Competition and Innovation Act (BPCIA) and licensed as a biologic.

What matters for risk assessment

Determine whether the relevant vasopressin analogue is licensed as a biologic (BLA) or as an NDA/ANDA product.
For typical vasopressin-like products licensed under standard drug pathways, ANDA/505(j) is the pathway rather than biosimilar competition.

Which licensing deals shape market outcomes for vasopressin and analogues?

Featured snippet: Licensing is common when patent estates combine drug product and method-of-use claims with uncertain design-around paths. In practice, settlements and agreements can specify launch timing and/or royalties tied to sales.

Where licensing tends to show up

Near the ANDA “patent cliff,” especially when a generic filer wants a clean route to launch.
When a patent holder insists on market exclusivity through multiple overlapping patents.

How does international coverage differ for vasopressin and analogues patents?

Featured snippet: Patent term and enforcement vary by jurisdiction due to differences in patent term adjustments, pediatric extensions, and local patentability standards, changing the practical launch window for generics.

Key cross-border considerations

Europe (EP): patent term and supplementary protection certificates can extend exclusivity beyond US clocks for certain drug product arrangements.
UK post-Brexit: comparable but not identical mechanics for adjustments and litigation.
Canada and Australia: different regulatory linkage mechanisms can shift the timing of challenges.

What manufacturing/IP barriers block generic manufacturing for this class?

Featured snippet: The most common IP barrier is the combination of formulation stability requirements and process claims that are hard to replicate outside the branded manufacturer’s controlled process.

Non-infringement challenges

Even if a generic hits the same label concentration, it may diverge in stabilizers or pH.
Even if formulation is matched, process and purification steps can differ and still trigger process-claim assertions if claims cover generic-equivalent steps.

How do vasopressin and analogues compare commercially within H01BA?

Featured snippet: Commercial performance is driven less by class-level demand and more by each molecule’s label breadth, route (nasal vs injectable), tender dynamics, and the status of patents tied to its specific dosage forms.

Competitive landscape dynamics

Branded pricing power persists while at least one enforceable drug product patent remains.
Once generic entry occurs, pricing often compresses quickly, but availability may remain episodic if manufacturing capacity is constrained for sterile peptide production.

Key Takeaways

ATC H01BA market outcomes are determined product-by-product by Orange Book-listed patent estates, not by the ATC class label.
Patent enforcement most often centers on drug product formulation and manufacturing/process claims, with method-of-use patents elevating risk when ANDA label matches the patented regimen.
Generic entry timing depends on the overlap of (1) unexpired patents for the exact dosage form and (2) indication scope certified in ANDA litigation strategy.
Biosimilar frameworks typically do not apply unless a particular vasopressin analogue is licensed as a biologic under BPCIA.
International launch windows can differ materially due to supplementary protection certificates and local patent term adjustments.

FAQs

What does an Orange Book “drug product” patent mean for vasopressin generic risk?
How do method-of-use patents for diabetes insipidus affect ANDA label approvals for vasopressin analogues?
Do process patents for peptide manufacturing typically require near-identical synthesis steps to avoid infringement?
What settlement terms most often govern launch timing for vasopressin analogue generics facing multiple unexpired patents?
When does international patent term extension (eg, SPCs) delay vasopressin analogue generic entry compared with the US?

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. Drug Approval and Databases: Orange Book and Hatch-Waxman related guidance materials. U.S. Food and Drug Administration.
21 U.S.C. § 355 (Hatch-Waxman framework) and related FDA regulations on ANDA submissions and patent certifications.